Xeris Biopharma Holdings, Inc. (LON:0A8E)

Market Cap	840.32M +98.6%
Revenue (ttm)	197.99M +42.0%
Net Income	-11.64M
EPS	-0.08
Shares Out	n/a
PE Ratio	n/a
Forward PE	31.75
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,129
Average Volume	1,851
Open	6.89
Previous Close	6.97
Day's Range	6.80 - 6.90
52-Week Range	3.45 - 10.09
Beta	0.94
RSI	40.11
Earnings Date	Mar 2, 2026

About Xeris Biopharma Holdings

Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adul...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2005
• Employees: 394
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0A8E

Financial Performance

In 2024, Xeris Biopharma Holdings's revenue was $203.07 million, an increase of 23.89% compared to the previous year's $163.91 million. Losses were -$54.84 million, -11.92% less than in 2023.

Financial numbers in USD